Compare LGND & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGND | PBLS |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 1997 | 2026 |
| Metric | LGND | PBLS |
|---|---|---|
| Price | $306.50 | $31.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $256.29 | N/A |
| AVG Volume (30 Days) | 172.3K | ★ 707.2K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2886.36 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $141,102,000.00 | N/A |
| Revenue This Year | $1.25 | N/A |
| Revenue Next Year | $19.41 | N/A |
| P/E Ratio | $192.70 | ★ N/A |
| Revenue Growth | ★ 29.48 | N/A |
| 52 Week Low | $175.89 | $25.56 |
| 52 Week High | $326.63 | $42.49 |
| Indicator | LGND | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 37.75 |
| Support Level | $286.99 | $26.42 |
| Resistance Level | $322.06 | $33.65 |
| Average True Range (ATR) | 9.45 | 3.26 |
| MACD | 3.06 | -0.93 |
| Stochastic Oscillator | 77.12 | 14.63 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.